Who we are
Measurement and modulation of the gut microbiome in health and disease presents the opportunity to impact medicine in an entirely new and unexplored way.
Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Diseases (IBD), metabolic diseases, and related disorders.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. Opening up a new field of therapeutic targets discovery in the microbiome and allowing the innovative repositioning of existing compounds targeting this new organ.
Paris, France – 12 November 2014 Enterome enters into a microbiome-based development collaboration with AbbVie in Crohn’s disease. Collaboration...12 November 2014
Paris, France – 14 October 2014 Enterome named as a winner of the Entente Life Sciences Investment Forum 2014,...15 October 2014